APPLICATION OF THE CYP3A4 SELECTIVE MECHANISM-BASED INACTIVATOR CYP3CIDE TO DELINEATE CYP3A4 AND CYP3A5 CONTRIBUTIONS TO THE METABOLISM OF CYP3A CLEARED DRUGS

被引：0
|
作者：
Tseng, Elaine [1 ]
Walsky, Robert L. [2 ]
Luzietti, Rick [2 ]
Harris, Jennifer [2 ]
Kosa, Rachel E. [1 ]
Zientek, Michael A. [3 ]
Goosen, Theunis C. [1 ]
Obach, R. Scott [1 ]
机构：
[1] Pfizer Global Res & Dev, Groton, CT USA
[2] AstraZeneca, Waltham, MA USA
[3] Pfizer Global Res & Dev, La Jolla, CA USA
来源：
DRUG METABOLISM REVIEWS | 2014年 / 45卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：77 / 77
页数：1
相关论文
共 50 条
  • [41] Pharmacogenetics of Carbamazepine: A Systematic Review on CYP3A4 and CYP3A5 Polymorphisms
    Riffi, Rachda
    Boughrara, Wefa
    Chentouf, Amina
    Ilias, Wassila
    Brahim, Narimene Malika Taieb
    Berrebbah, Amel Alioua
    Belhoucine, Fatma
    CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS, 2024, 23 (12) : 1463 - 1473
  • [42] Effect of CYP3A4* 22, CYP3A5* 3, and CYP3A Combined Genotypes on Cyclosporine, Everolimus, and Tacrolimus Pharmacokinetics in Renal Transplantation
    Moes, D. J. A. R.
    Swen, J. J.
    den Hartigh, J.
    van der Straaten, T.
    van der Heide, J. J. Homan
    Sanders, J. S.
    Bemelman, F. J.
    de Fijter, J. W.
    Guchelaar, H. J.
    CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2014, 3 (02):
  • [43] MD Investigation on the Interaction between Carbamazepine and Two CYP Isoforms, CYP3A4 and CYP3A5
    Liu, Shuhui
    Xu, Yang
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (03)
  • [44] Role of CYP3A4 in kinase inhibitor metabolism and assessment of CYP3A4 activity
    Mikus, Gerd
    Foerster, Kathrin Isabelle
    TRANSLATIONAL CANCER RESEARCH, 2017, 6 : S1592 - S1599
  • [45] Investigation of the structural basis for the differential metabolism of glucocorticoids by CYP3A4 and CYP3A5 enzymes
    Shahrokh, Kiumars
    Yost, Garold S.
    Cheatham, Thomas E., III
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2013, 245
  • [46] CYP3A4, CYP3A5, and CYP3A43 genotypes and haplotypes in the etiology and severity of prostate cancer
    Zeigler-Johnson, C
    Friebel, T
    Walker, AH
    Wang, YT
    Spangler, E
    Panossian, S
    Patacsil, M
    Aplenc, R
    Wein, AJ
    Malkowicz, SB
    Rebbeck, TR
    CANCER RESEARCH, 2004, 64 (22) : 8461 - 8467
  • [47] SEQUENCE OF THE 5'-FLANKING REGION OF CYP3A5 - COMPARATIVE-ANALYSIS WITH CYP3A4 AND CYP3A7
    JOUNAIDI, Y
    GUZELIAN, PS
    MAUREL, P
    VILAREM, MJ
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1994, 205 (03) : 1741 - 1747
  • [48] CYP3A5*3 and CYP3A4*18 single nucleotide polymorphisms in a Chinese population
    Hu, YF
    He, J
    Chen, GL
    Wang, D
    Liu, ZQ
    Zhang, C
    Duan, LF
    Zhou, HH
    CLINICA CHIMICA ACTA, 2005, 353 (1-2) : 187 - 192
  • [49] Metabolism of Quetiapine by CYP3A4 and CYP3A5 in Presence or Absence of Cytochrome B5
    Bakken, Gry Vibeke
    Rudberg, Ida
    Christensen, Hege
    Molden, Espen
    Refsum, Helge
    Hermann, Monica
    DRUG METABOLISM AND DISPOSITION, 2009, 37 (02) : 254 - 258
  • [50] Mechanism-based inhibition of CYP3A4 by zafirlukast
    Lanza, DL
    Skordos, KW
    Borges, CR
    Yost, GS
    DRUG METABOLISM REVIEWS, 2004, 36 : 285 - 285
12345